MoonLake Immunotherapeutics traded as low as $5.95 and last traded at $6.24, with a volume of 79166804 shares traded. According to data from MarketBeat, MoonLake Immunotherapeutics has an average rating of “Hold” and a consensus target price of $57.00. As a group, equities analysts forecast that MoonLake Immunotherapeutics will post -1.79 earnings per share for the current fiscal year. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland. Featured StoriesReceive News & Ratings for MoonLake Immunotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MoonLake Immunotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.